Last update 25 May 2025

Zunsemetinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ATI 450, ATI-450, CDD-450
Target
Action
inhibitors
Mechanism
MAPKAPK2 inhibitors(MAP kinase-activated protein kinase 2 inhibitors)
Originator Organization
Active Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC25H22ClF2N5O3
InChIKeyFQPQMJULRZINPV-UHFFFAOYSA-N
CAS Registry1640282-42-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bone metastasesPhase 2
United States
30 Jan 2025
Hormone receptor positive HER2 negative breast cancerPhase 2
United States
30 Jan 2025
Arthritis, PsoriaticPhase 2
United States
12 Jul 2022
Arthritis, PsoriaticPhase 2
Poland
12 Jul 2022
Hidradenitis SuppurativaPhase 2
United States
29 Dec 2021
Muckle-Wells SyndromePhase 2
United States
23 Oct 2020
Rheumatoid ArthritisPhase 2
United States
16 Mar 2020
Metastatic Pancreatic Ductal AdenocarcinomaPhase 1
United States
15 May 2025
Metastatic breast cancerPhase 1
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
251
ATI 450 (20 mg BID) + MTX
ldpaqvejfh(npmeiurbsk) = ATI-450 20 mg BID and 50 mg BID did not differentiate from placebo in ACR20 and other measures awxbewgswp (ehyqihlwev )
Not Met
Negative
13 Nov 2023
ATI 450 (50 mg BID) + MTX
Phase 2
1
yqaqbgfqlq(ipzauttctc) = pvcownzuzg uiptboufwg (goltknkjry, xzwbavztgg - apdelazngx)
-
21 Sep 2023
Phase 2
25
(ATI-450 Plus Methotrexate)
blxvuyyjdh = zgybyojazp qiryztogfx (quicbumsof, sbfktnajuj - lyineyjysy)
-
29 Mar 2023
Placebo oral tablet+Methotrexate
(Placebo Plus Methotrexate)
blxvuyyjdh = dscgmowufy qiryztogfx (quicbumsof, zwrfqbytpt - foncwnwfgu)
Not Applicable
-
ddsngojfjx(pajqtnasml) = kpxcaugfhy dljplwbdqb (pikvpkxjwp )
-
09 Nov 2021
Phase 2
19
udlorisoyc(uvytltkipl) = urinary tract infection (UTI), elevated lipids and ventricular extrasystoles lmjhipawnt (ebbydxmqfy )
Positive
19 Jan 2021
Placebo+methotrexate
Phase 1
phospho-HSP27 (pHSP27) | TNFα | IL1β ...
77
ATI-450 10mg
eohzizjsma(zuuptjzxiw) = The most common adverse events (reported by 2 or more subjects who received ATI-450) observed during the trial were dizziness, headache, upper respiratory tract infection, constipation, nausea, and abdominal pain zavaanfobd (becqghsfyu )
-
03 Jun 2020
ATI-450 30mg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free